[go: up one dir, main page]

PE20010226A1 - Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica - Google Patents

Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica

Info

Publication number
PE20010226A1
PE20010226A1 PE2000000311A PE0003112000A PE20010226A1 PE 20010226 A1 PE20010226 A1 PE 20010226A1 PE 2000000311 A PE2000000311 A PE 2000000311A PE 0003112000 A PE0003112000 A PE 0003112000A PE 20010226 A1 PE20010226 A1 PE 20010226A1
Authority
PE
Peru
Prior art keywords
peg
treatment
preparation
medicinal product
myelocytic leukemia
Prior art date
Application number
PE2000000311A
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20010226A1 publication Critical patent/PE20010226A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE AL USO DE 4,5 µg/Kg A 9,0 µg/Kg DE INTERFERON ALFA 2a O ALFA 2b MODIFICADO CON PEG; TAMBIEN SE REFIERE AL USO CON UNA CANTIDAD EFECTIVA DE CITARABINA, ADMINISTRADOS UNA VEZ A LA SEMANA POR UN PERIODO DE AL MENOS 6 MESES EN PACIENTES SIN TRATAMIENTO PREVIO AL QUE SE LE HA DIAGNOSTICADO RECIENTEMENTE LEUCEMIA MIELOCITICA CRONICA O EXPERIMENTO ALGUN TRATAMIENTO O ES INTOLERANTE O RESISTENTE AL INTERFERON ALFA PARA LOGRAR UNA RESPUESTA CITOGENETICA COMPLETA O PARCIAL
PE2000000311A 1999-04-08 2000-04-06 Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica PE20010226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28836999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
PE20010226A1 true PE20010226A1 (es) 2001-02-26

Family

ID=23106810

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000311A PE20010226A1 (es) 1999-04-08 2000-04-06 Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica

Country Status (21)

Country Link
EP (2) EP1535624A1 (es)
JP (2) JP2000309541A (es)
CN (1) CN1364089A (es)
AR (1) AR023390A1 (es)
AT (1) ATE297216T1 (es)
AU (2) AU777456B2 (es)
BR (1) BR0009642A (es)
CA (1) CA2303765A1 (es)
CO (1) CO5170411A1 (es)
DE (1) DE60020635T2 (es)
DK (1) DK1043024T3 (es)
ES (1) ES2243166T3 (es)
HU (1) HUP0200731A3 (es)
MY (1) MY127276A (es)
NO (1) NO20014850L (es)
NZ (1) NZ514417A (es)
PE (1) PE20010226A1 (es)
PT (1) PT1043024E (es)
TW (1) TWI271196B (es)
WO (1) WO2000061173A2 (es)
ZA (1) ZA200108172B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
HK1032348A1 (en) 2001-07-20
JP2007070367A (ja) 2007-03-22
CO5170411A1 (es) 2002-06-27
WO2000061173A2 (en) 2000-10-19
HUP0200731A3 (en) 2002-09-30
NO20014850D0 (no) 2001-10-05
AR023390A1 (es) 2002-09-04
ES2243166T3 (es) 2005-12-01
EP1043024A3 (en) 2000-12-20
JP2000309541A (ja) 2000-11-07
CA2303765A1 (en) 2000-10-08
DK1043024T3 (da) 2005-07-04
EP1043024B1 (en) 2005-06-08
EP1043024A2 (en) 2000-10-11
AU4451500A (en) 2000-11-14
WO2000061173A3 (en) 2001-01-25
ATE297216T1 (de) 2005-06-15
HUP0200731A2 (en) 2002-08-28
AU2004242456B2 (en) 2007-02-15
DE60020635D1 (de) 2005-07-14
NZ514417A (en) 2003-10-31
BR0009642A (pt) 2002-01-08
ZA200108172B (en) 2003-01-06
AU777456B2 (en) 2004-10-14
DE60020635T2 (de) 2006-05-04
NO20014850L (no) 2001-12-07
MY127276A (en) 2006-11-30
EP1535624A1 (en) 2005-06-01
AU2004242456A1 (en) 2005-01-20
PT1043024E (pt) 2005-10-31
TWI271196B (en) 2007-01-21
CN1364089A (zh) 2002-08-14

Similar Documents

Publication Publication Date Title
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
ATE198269T1 (de) Sublingual oder bukkal verabreichte arzneistoffe mit gesteuerter freisetzung
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
AR008444A1 (es) Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
CA2124677A1 (en) Immunopotentiatory agents and physiologically acceptable salts thereof
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
TR200101633T2 (tr) Farmasötik bileşim
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
HRPK20030734B3 (en) A combination comprising combretastatin and anticancer agents
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
ES2059457T3 (es) Utilizacion de bezafibrato para el tratamiento de la diabetes.
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
PE20010226A1 (es) Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
MX9304075A (es) Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
RU97106927A (ru) Способ профилактики осложнений у кардиохирургических больных с хроническим септическим эндокардитом
SE0203817D0 (sv) New composition
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.

Legal Events

Date Code Title Description
FC Refusal